Enterprise Therapeutics

Mother helps child to use a nebuliser
#Clinical trial #Cystic fibrosis #Enterprise Therapeutics

Cystic fibrosis treatment could improve lung function 

A new treatment for cystic fibrosis (CF) could improve lung function in patients, results suggest.  ETD001, developed by biopharmaceutical company Enterprise Therapeutics, was trialled in a Phase II study as an inhaled treatment in the 10% of people with CF with the highest unmet medical need, who do… Read More

#News

#Cystic fibrosis #Enterprise Therapeutics #Phase II trial

Clinical trial will assess novel approach to cystic fibrosis

Enterprise Therapeutics announced it has dosed the first person with cystic fibrosis (pwCF) in its Phase IIa trial of ETD001. ETD001, a low molecular weight compound with first-in-class potential, targets the epithelial sodium channel (ENaC) in the airway epithelium to increase the hydration and clearance of… Read More

#News

Child with cystic fibrosis on ventilator
#Animal models #Cystic fibrosis #Enterprise Therapeutics #Preclinical development

ENaC blocker enhances mucus clearance in cystic fibrosis models

A preclinical study in cystic fibrosis sheep models has demonstrated that low doses of the ENaC blocker ETD001 can enhance airway mucus clearance with a long duration of action. The study indicates that ETD001, at a dose level that was well tolerated in healthy volunteers, provides… Read More

#News